A randomised controlled trial to compare the cost-effectiveness of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine.

Health technology assessment (Winchester, England)

Volumn 9, Issue 16, 2005, Pages

  Peveler, R ^a   Kendrick, T ^b   Buxton, M ^b   Longworth, L ^b   Baldwin, D ^b   Moore, M ^b   Chatwin, J ^b   Goddard, J ^b   Thornett, A ^b   Smith, H ^b   Campbell, M ^b   Thompson, C ^b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

LOFEPRAMINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DEPRESSION; ECONOMICS; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; PSYCHOLOGICAL RATING SCALE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS, TRICYCLIC; COST-BENEFIT ANALYSIS; DEPRESSIVE DISORDER; FEMALE; HUMANS; LINEAR MODELS; LOFEPRAMINE; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; SEROTONIN UPTAKE INHIBITORS;

EID: 84891719121     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta9160     Document Type: Article

References (0)